Treatment of multiple myeloma (MM) is now very complex and costly. However, survival benefits achieved with new therapies in clinical trials are not being seen in clinical practice, in part because many MM patients stop therapy early, often due to side-effects.
The MY-PROMPT-2 trial tests whether real-time symptom feedback using patient-reported outcome measures improves duration on treatment, leading to better patient outcomes and more efficient use of these high-cost medicines.
MY-PROMPT-2 is a collaboration between the Transfusion Research Unit (TRU) at Monash University and AMaRC.
Trial Management Centre: Transfusion Research Unit, Monash University
STATUS
Actively recruiting
CURRENT ENROLMENT
19 Patients
Recruitment updated as of December 2024
STUDY DESIGN
A parallel, non-blinded, multicentre, Bayesian randomised control trial
OPTIONAL SUB-STUDIES
Qualitative Interview Sub-Study
This sub-study will explore patient, clinician, and hospital staff's experience of the trial and the intervention.
Economic Evaluation Sub-Study
This sub-study will look to determine the cost-effectiveness of real-time feedback of patient-reported outcome measures.
TRIAL PRINCIPAL INVESTIGATORS
Coordinating Principal Investigator: Professor Andrew Spencer, Monash University & AMaRC
Dr Sueh-li Lim, Alfred Health
TIME FRAME
2023 – 2027
PARTICIPANTS
Patients with relapsed multiple myeloma receiving standard-of-care treatment (daratumumab, lenalidomide, or carfilzomib based therapies) who are registered on the MRDR.
SITE LOCATIONS
Alfred Hospital, VIC
Epworth HealthCare, VIC
Princess Alexandra Hospital, QLD
Royal Prince Alfred Hospital, NSW
Austin Health, VIC